Glucocorticoids are among the many most generally used anti-inflammatory and immunosuppressive medication. Nonetheless, their extended administration is related to a variety of adversarial unintended effects together with long-lasting immunosuppression. On this research, we aimed to encapsulate two generally used glucocorticoids with completely different efficiency and length, hydrocortisone and dexamethasone, into poly(lactic-co-glycolic acid) (PLGA) nanoparticles with the objective to boost their therapeutic efficacy and security profile. We evaluated their anti-inflammatory properties in two in vitro fashions various the timing of therapy administration based mostly on lipopolysaccharide M1-polarized macrophages, key effectors of the innate immune system. Our outcomes demonstrated that, for each methods, drug-loaded nanoparticles considerably diminished the expression of interleukin-6, a pro-inflammatory cytokine, extra successfully than the free medication. Nonetheless, in one of many methods, whereas free medication induced upregulation of interleukin-10, a key anti-inflammatory cytokine, no such impact was noticed with the nanoparticle-based formulations. These findings counsel that encapsulating glucocorticoids into PLGA could present a extra managed and selective modulation of the inflammatory response, probably lowering the chance of extreme immunosuppression. Total, our research highlights the potential of PLGA nanoparticles as nanocarrier to enhance glucocorticoid effectivity by selling a extra balanced modulation of macrophage polarization in irritation responses.
